GOVX

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. Its lead clinical program is GEO-CM04S1, a COVID-19 vaccine, which is in three phase II clinical trials, being evaluated as a primary vaccine for immunocompromised patients, such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient; a booster vaccine in patients with chronic lymphocytic leukemia (CLL); and a COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology, the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin, having completed a multicenter Phase I/II clinical trial for advanced head and neck cancers. It is developing GEO-MVA, a vaccine targeting Mpox and smallpox. Its other product candidates include GEO-EM01-Z, GEO-EM01-S, GEO-MM01, GEO-ZM02 and others.

Wall Street analysts forecast GOVX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GOVX is 12.00 USD with a low forecast of 10.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

GeoVax Labs Inc revenue for the last quarter amounts to 0.00 USD, decreased -100.00 % YoY.

GeoVax Labs Inc. EPS for the last quarter amounts to -0.31 USD, decreased -65.93 % YoY.

GeoVax Labs Inc (GOVX) has 17 emplpoyees as of December 15 2025.

Today GOVX has the market capitalization of 11.13M USD.